Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab

Neurology

Volumn 76, Issue 15, 2011, Pages 1310-1315

  Pellkofer, H L ^a   Krumbholz, M ^a,b   Berthele, A ^c   Hemmer, B ^c   Gerdes, L A ^a   Havla, J ^a   Bittner, R ^a,b   Canis, M ^a   Meinl, E ^a,b   Hohlfeld, R ^a   Kuempfel, T ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX PLANCK INSTITUTE OF NEUROBIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APRIL PROTEIN; AQUAPORIN 4; AZATHIOPRINE; BETA INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN; METHOTREXATE; MITOXANTRONE; NATALIZUMAB; PROTEIN ANTIBODY; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ABSENCE OF SIDE EFFECTS; ADNEXITIS; ADULT; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; MALE; MYELOOPTIC NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; THROMBOSIS; UROGENITAL TRACT INFECTION; UROSEPSIS;

ADOLESCENT; ADULT; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; AQUAPORIN 4; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; COHORT STUDIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKOCYTE COUNT; LONGITUDINAL STUDIES; MALE; NEUROMYELITIS OPTICA; OSMOLAR CONCENTRATION; PROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 79954613355     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182152881     Document Type: Article

References (35)

1. Allbutt T. On the ophthalmoscopic signs of spinal disease. Lancet 1870;1:76-78.
2. Devic E. Myelite subaiguë compliquée de névrite optique. Bull Med 1894;8:1033-1034.
3. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999;53:1107-1114. (Pubitemid 29442132)
4. Bennett JL, Lam C, Kalluri SR, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol 2009;66:617-629.
5. Bradl M, Misu T, Takahashi T, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009;66:630-643.
6. Jarius S, boul-Enein F, Waters P, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008;131:3072-3080.
7. Matsushita T, Isobe N, Matsuoka T, et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibodynegative opticospinal multiple sclerosis in Japanese. Mult Scler 2009;15:834-847.
8. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581. (Pubitemid 38758544)
9. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358:676-688. (Pubitemid 351240747)
10. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008;65:1443-1448.
11. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006;66:1485-1489. (Pubitemid 43958540)
12. Naismith RT, Piccio L, Lyons JA, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52- week phase II trial. Neurology 2010;74:1860-1867.
13. Kalluri SR, Illes Z, Srivastava R. Quantification and functional characterization of antibodies to native aquaporin-4 in neuromyelitis optica. Arch Neurol 2010;67:1201-1208.
14. Pellkofer HL, Suessmair C, Schulze A, Hohlfeld R, Kuempfel T. Course of neuromyelitis optica during inadvertent pregnancy in a patient treated with rituximab. Mult Scler 2009;15:1006-1008.
15. Pellkofer HL, Hohlfeld R, Kuempfel T. Thirty-one episodes of myelitis and optic neuritis in a woman with neuromyelitis optica and systemic lupus erythematosus. Arch Neurol 2010;67:779-780.
16. Papeix C, Vidal JS, de SJ, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 2007;13:256-259. (Pubitemid 46592781)
17. Stuve O, Leussink VI, Frohlich R, et al. Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis. Arch Neurol 2009; 66:259-261.
18. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008;58:2993-2999.
19. Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 2010; 133:349-361.
20. Takahashi T, Fujihara K, Nakashima I, et al. Antiaquaporin- 4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007;130:1235-1243. (Pubitemid 47355956)
21. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 2003;48:2146-2154. (Pubitemid 36959194)
22. Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 2009;28:251-255.
23. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005;64:1270-1272.
24. Cross SA. Rethinking neuromyelitis optica (Devic disease). J Neuroophthalmol 2007;27:57-60. (Pubitemid 46597642)
25. Stuve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsingremitting multiple sclerosis. Arch Neurol 2005;62:1620-1623. (Pubitemid 41434570)
26. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005;62:258-264. (Pubitemid 40204747)
27. Rastetter W, Molina A, White CA. Rituximab: expanding role in therapy for lymphomas and autoimmune diseases. Annu Rev Med 2004;55:477-503. (Pubitemid 38316738)
28. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008;4: 557-567.
29. Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20- T cells by rituximab treatment. Arthritis Rheum 2009;60:3563-3571.
30. Stasi R, Del PG, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 2007;110:2924-2930. (Pubitemid 350006946)
31. Stasi R, Cooper N, Del PG, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 2008;112:1147-1150.
32. Okada K, Matsushita T, Kira J, Tsuji S. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 2010;74:177-178.
33. Krumbholz M, Faber H, Steinmeyer F, et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008;131:1455-1463. (Pubitemid 351806460)
34. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-703. (Pubitemid 46707145)
35. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximabtreated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167.